While the significance of DMR in tumor progression is well established, how to render it feasible to achieve beneficial effects without inducing systemic toxicities in therapy remains a controversial topic.[35, 49] Besides, the same regimen may lead to diverse outcomes depending on genetic and environmental factors.[50] Previous results demonstrated that PCSK9, an encouraging target for cancer therapy, participates in regulating tumor progression via DMR (Figure 1I,J). The gene discussed is PCSK9; the disease is cancer.